Traws Pharma, Inc.
TRAW
$1.53
$0.000.00%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| SG&A Expenses | 66.79% | 29.56% | -10.58% | 58.83% | 3.32% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 18.06% | 66.98% | 27.30% | -14.94% | -21.97% |
| Operating Income | -18.29% | -67.73% | -27.64% | 15.07% | 22.18% |
| Income Before Tax | -615.15% | -78.84% | -2,797.48% | 13.71% | 22.80% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -615.15% | -78.84% | -2,797.48% | 13.71% | 22.80% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -615.15% | -78.84% | -2,797.48% | 13.71% | 22.80% |
| EBIT | -18.29% | -67.73% | -27.64% | 15.07% | 22.18% |
| EBITDA | -18.35% | -67.86% | -27.66% | 15.10% | 22.20% |
| EPS Basic | 634.44% | -56.25% | -2,301.69% | 14.06% | 23.12% |
| Normalized Basic EPS | -95.19% | -56.25% | -10.76% | 14.06% | 23.12% |
| EPS Diluted | 634.44% | -56.25% | -2,301.69% | 14.06% | 24.00% |
| Normalized Diluted EPS | -95.19% | -56.25% | -10.76% | 14.06% | 23.12% |
| Average Basic Shares Outstanding | 266.38% | 14.45% | 20.64% | 0.39% | 0.42% |
| Average Diluted Shares Outstanding | 266.38% | 14.45% | 20.64% | 0.39% | 0.42% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |